Effects of pentoxifylline on olfactory sensitivity: a postmarketing surveillance study.

Smell & Taste Clinic, Department of Otorhinolaryngology, University of Dresden Medical School, Dresden, Germany.
Archives of otolaryngology--head & neck surgery (Impact Factor: 1.75). 04/2009; 135(3):291-5. DOI: 10.1001/archoto.2008.524
Source: PubMed

ABSTRACT To investigate the effect of pentoxifylline, an unspecific phosphodiesterase inhibitor, on olfactory function.
Longitudinal study.
Nineteen patients who received pentoxifylline to treat inner-ear conditions.
Evaluation of olfactory function (ie, odor threshold, odor discrimination, and odor identification) before and after administration of pentoxifylline and assessment of nasal airflow.
Administration of pentoxifylline had no significant effect on nasal airflow (P = .84). After administration of pentoxifylline, patients demonstrated a decrease in odor threshold toward lower odor concentrations (P = .01). The odor threshold shift after administration of pentoxifylline was more pronounced in younger patients than in older patients (correlation between age and change in odor threshold: r = -.72; P = .001). No such changes were observed for suprathreshold olfactory tasks (odor discrimination and odor identification). Six of the 19 patients were found to have hyposmia. Two patients demonstrated a clinically significant decrease in odor threshold after drug administration.
The present findings may indicate a role for pentoxifylline in the treatment of olfactory loss. Double-blind, placebo-controlled studies are needed to verify whether pentoxifylline can improve olfactory sensitivity in patients with olfactory disorders.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The negative consequences of olfactory dysfunction for the quality of life are not widely appreciated and the condition is therefore often ignored or trivialized. 1,000 patients with olfactory dysfunction participated in an online study by submitting accounts of their subjective experiences of how they have been affected by their condition. In addition, they were given the chance to answer 43 specific questions about the consequences of their olfactory dysfunction. Although there are less practical problems associated with impaired or distorted odor perception than with impairments in visual or auditory perception, many affected individuals report experiencing olfactory dysfunction as a debilitating condition. Smell loss-induced social isolation and smell loss-induced anhedonia can severely affect quality of life. Olfactory dysfunction is a serious condition for those affected by it and it deserves more attention from doctors who treat affected patients as well as from scientist who research treatment options.
    BMC Ear Nose and Throat Disorders 07/2013; 13(1):8. DOI:10.1186/1472-6815-13-8
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Smell and taste disorders can markedly affect the quality of life. In recent years we have become much better in the assessment of the ability to smell and taste. In addition, information is now available to say something about the prognosis of individual patients. With regard to therapy there also seems to be low but steady progress. Of special importance for the treatment is the ability of the olfactory epithelium to regenerate.
    01/2011; 10:Doc04. DOI:10.3205/cto000077
  • [Show abstract] [Hide abstract]
    ABSTRACT: Theophylline, used in the treatment for various pulmonary pathologies, is usually given orally with drug levels measured primarily in blood serum and occasionally in saliva. Although theophylline treatment is now not commonly used it has been effective to correct smell loss (hyposmia). This is important because 21 million people in the United States exhibit hyposmia and oral theophylline has corrected hyposmia in about 50% of these patients. This result suggests that oral theophylline may result in the drug not only appearing in the serum but also in nasal mucus, thereby playing a role in correcting hyposmia. No prior report of theophylline in nasal mucus has been made and no comparison of levels in nasal mucus, blood serum, or saliva has been previously reported. The aim was to determine, after oral theophylline treatment, if it is present in nasal mucus and, if present, to compare the levels with those in serum and saliva. Oral theophylline was given to 23 hyposmic patients at daily doses of 200, 300, 400, 600, and 800 mg for periods of 2-10 months. During each period, blood serum, saliva, and nasal mucus were collected and theophylline measured in each fluid. Theophylline was found in nasal mucus and in saliva and blood serum at each drug dose in each patient to whom it was given. The mean level of theophylline in nasal mucus was 74% that of serum; mean level in saliva was 67% of serum; mean level in nasal mucus was 111% that in saliva. Theophylline is present in nasal mucus after oral administration. Levels in nasal mucus reflect blood and saliva levels in a consistent manner and offer a simple convenient noninvasive method to monitor theophylline doses of the oral drug.
    Therapeutic drug monitoring 02/2012; 34(2):217-21. DOI:10.1097/FTD.0b013e3182492a20 · 1.93 Impact Factor